- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the US since January 2026. European approval is not expected after the CHMP's final negative opinion in October 2026.
- Why 4/10
- YARTEMLEA is already FDA-approved and commercially launched. There is no pending regulatory decision for this drug (the EU application was definitively rejected). The next catalyst is the Q3 2026 earnings report on November 11, 2026, which is a commercial update, not a binary regulatory event. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
Watch the Q3 2026 earnings report on November 11, 2026 for YARTEMLEA's sales trajectory. The key question is whether the 190% sequential growth rate from Q1 to Q2 can be sustained or if the launch is plateauing. Separately, the zaltenibart (OMS906) Phase 3 PNH data readout expected in Q4 2026 is a major pipeline catalyst for the stock, though it is a different drug.
Price Chart
Executive Summary
YARTEMLEA (narsoplimab) is the first and only FDA-approved treatment for TA-TMA, a rare and often fatal complication of stem cell transplants. Omeros launched the drug in the US in January 2026, and sales have ramped quickly from $11.1M gross in Q1 to $32.2M gross in Q2 2026, driving the company to operating break-even. However, the European Medicines Agency definitively rejected the drug in October 2026, closing off a major market. The stock trades around $18 with a mean analyst target of $27.50, reflecting optimism about US commercial momentum balanced against the EU setback and the need to prove sustained revenue growth.
How It Works
YARTEMLEA is a lab-engineered antibody that blocks MASP-2, a protein that drives a part of the immune system called the lectin pathway of complement. By blocking MASP-2, the drug stops the immune system from attacking and damaging blood vessels without disabling other important immune defenses. It is given as an IV infusion once or twice a week.
Trial Status
YARTEMLEA was approved by the FDA on December 24, 2025 based on a single-arm Phase 2 trial (TMA-001, NCT02222545) of 28 adult patients plus 19 patients from an expanded access program. The drug achieved a 61% complete response rate. It is now commercially launched in the US. A European marketing application was rejected by the EMA's CHMP in June 2026, and a re-examination in October 2026 upheld the negative opinion.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings report on November 11, 2026, which will show YARTEMLEA sales trajectory
- Zaltenibart (OMS906) Phase 3 PNH data readout expected in Q4 2026 (a separate drug, but material for the stock)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
OMEROS CORP 8-K OMER ·Originating report